Senores Pharmaceuticals Limited will host investor meetings in Mumbai on August 25, 2026. The company announced the schedule pursuant to Regulation 30(6) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015.

The interactions, hosted by Antique Stock Broking, are scheduled for 11:00 am onwards. The format includes both group and one-on-one meetings held in a physical setting at Mumbai.

Meeting Details

Company officials stated that discussions during the interactions will be based on publicly available information. No unpublished price-sensitive information (UPSI) is intended to be discussed.

Deval Rajnikant Shah, Whole-Time Director & CFO of Senores Pharmaceuticals Limited, signed the intimation dated August 20, 2026. The company noted that changes to the schedule may occur due to exigencies on the part of the host or the company.

Senores Pharmaceuticals Limited has announced the outcome of its postal ballot, with shareholders approving all eight resolutions put to vote through the remote e-voting process. The e-voting window remained open from July 5, 2026 at 9:00 a.m. (IST) to August 3, 2026 at 5:00 p.m. (IST). The scrutinizer's report, prepared by Mukesh H. Shah & Co., Company Secretaries, was issued on August 4, 2026, confirming that all resolutions were passed with the requisite majority. The record date for the postal ballot was June 30, 2026, with a total of 36,498 shareholders on record as of that date.

Voting Process and Administration

The postal ballot notice, dated June 29, 2026, was dispatched electronically on July 2, 2026 to members whose e-mail addresses were registered with the Company, Share Transfer Registrar, or Depositories as on the cut-off date of June 30, 2026. In accordance with MCA Circulars, the notice was sent only in electronic form, with no hard copies dispatched. An advertisement was published in the English newspaper Financial Express and the Vernacular (Gujarati) newspaper Financial Express on July 3, 2026, notifying members of the e-voting facility. The e-voting platform was provided by MUFG Intime India Pvt. Ltd. (formerly known as Link Intime India Pvt. Ltd.), and the votes were unblocked after the conclusion of the e-voting period in the presence of two independent witnesses, Mr. Bharat Chaudhary and Mr. Dhruv Todi.

The scrutinizer noted that there were 11 invalid votes (18,085,228 shares) in Resolutions 1 to 5, attributable to related parties, while Resolutions 6 to 8 recorded no invalid votes. Additionally, one shareholder holding 160 shares voted for only 1 share.

Resolution-wise Voting Results

All eight resolutions were passed with the requisite majority. The following table summarises the voting outcome for each resolution:

Category-wise Participation

For Resolutions 1 to 5, the promoter and promoter group (holding 21,100,357 shares) did not participate in the voting, as they were classified as interested parties. Public Institutions holding 7,547,516 shares polled 3,313,297 votes (43.8992% of shares held), while Public Non-Institutions holding 17,405,715 shares polled 5,354,851 votes (30.7649% of shares held). The total shares on record stood at 46,053,588, with 8,668,148 total valid votes polled, representing 18.8219% of outstanding shares for these resolutions.

For Resolutions 6 to 8, the promoter and promoter group participated actively, polling 18,085,228 votes out of 21,100,357 shares held (85.7105%). Total valid votes polled for these resolutions stood at 26,753,376, representing 58.0918% of outstanding shares.

Key Resolutions: Related Party Transactions and Corporate Approvals

Resolutions 1 through 5 pertained to material related party transactions and were classified as ordinary resolutions requiring prior shareholder approval under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These covered transactions with:

• Havix Group INC. d/b/a Aavis Pharmaceuticals (direct RPT and inter-subsidiary RPT with Senores Pharmaceuticals INC.)
• Ratnatris Pharmaceuticals Private Limited
• Apnar Pharma Private Limited (direct RPT and inter-subsidiary RPT with Havix Group INC. d/b/a Aavis Pharmaceuticals)

Resolutions 6 and 7 were special resolutions seeking enhancement of existing limits for advancing loans, giving guarantees, and providing security under Sections 185 and 186 of the Companies Act, 2013, respectively. Resolution 8, also a special resolution, approved the variation in the objects and terms of utilisation of IPO proceeds along with an extension of the time limit for their utilisation. All three special resolutions saw no participation from interested promoter/promoter group shareholders, and all were passed with the requisite majority.